Evidence map›Paper›PMID 40197207›Full record

ArticleBMC infectious diseases2025

Correction: Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial.

M M B Horstink, D R Geel, C A den Uil, P E Deetman, H Endeman, A Abdulla, T M Bosch, W J R Rietdijk, F W Thielen, J J Haringman and 7 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

M M B HorstinkDepartment of Intensive Care, Maasstad Hospital, Rotterdam, The Netherlands. m.horstink@erasmusmc.nl.
D R GeelRotterdam Clinical Pharmacometrics Group, Erasmus MC, Rotterdam, The Netherlands.
C A den UilDepartment of Intensive Care, Maasstad Hospital, Rotterdam, The Netherlands.
P E DeetmanDepartment of Intensive Care, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
H EndemanDepartment of Intensive Care, OLVG, Amsterdam, The Netherlands.
A AbdullaRotterdam Clinical Pharmacometrics Group, Erasmus MC, Rotterdam, The Netherlands.
T M BoschDepartment of Clinical Pharmacology & Toxicology Maasstadlab, Maasstad Hospital, Rotterdam, The Netherlands.
W J R RietdijkDepartment of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands.
F W ThielenSchool of Health Policy & Management, Erasmus University, Erasmus Centre for Health Economics Rotterdam, Rotterdam, The Netherlands.
J J HaringmanDepartment of Intensive Care, Isala Hospital, Zwolle, The Netherlands.
P van VlietDepartment of Intensive Care Haaglanden Medical Center, The Hague, The Netherlands.
T A RijpstraDepartment of Intensive Care, Amphia, Breda, The Netherlands.
C BethlehemDepartment of Intensive Care, Frisius MC, Leeuwarden, The Netherlands.
A BeishuizenDepartment of Intensive Care, Medisch Spectrum Twente, Enschede, The Netherlands.
A E MullerDepartment of Medical Microbiology, Haaglanden Medical Center, The Hague, The Netherlands.
B C P KochRotterdam Clinical Pharmacometrics Group, Erasmus MC, Rotterdam, The Netherlands.
BULLSEYE investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40197207
PMCPMC11974154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.